Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report | Zendy

David Starks | Zendy; Deborah Prinz | Zendy; Amy J. Armstrong | Zendy; Lindsay Means | Zendy; Steven Waggoner | Zendy; Robert DeBernardo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report

Author(s) -

David Starks,

Deborah Prinz,

Amy J. Armstrong,

Lindsay Means,

Steven Waggoner,

Robert DeBernardo

Publication year - 2011

Publication title -

case reports in obstetrics and gynecology

Language(s) - English

Resource type - Journals

eISSN - 2090-6684

pISSN - 2090-6692

DOI - 10.1155/2011/837160

Subject(s) - etoposide , medicine , discontinuation , hypersensitivity reaction , chemotherapy , bleomycin , carboplatin , cisplatin , drug , yolk sac , oncology , pharmacology , embryo , biology , microbiology and biotechnology

Type I hypersensitivity reactions to intravenous administration of etoposide are extremely rare. Etoposide is an essential component of several chemotherapy regimens used in gynecologic oncology, and discontinuation of this drug during a course of treatment should only be due to severe patient intolerance. We report the successful use of intravenous etoposide phosphate as a substitute drug in a patient with a yolk sac tumor who manifested a Type I hypersensitivity to intravenous etoposide. The patient ultimately completed all 4 cycles of bleomycin, etoposide, cisplatin (BEP) using etoposide phosphate as a substitute drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research